ATE246923T1 - Dfmo und taxol zur behandlung bzw. vorbeugung von brustkrebs - Google Patents

Dfmo und taxol zur behandlung bzw. vorbeugung von brustkrebs

Info

Publication number
ATE246923T1
ATE246923T1 AT97910042T AT97910042T ATE246923T1 AT E246923 T1 ATE246923 T1 AT E246923T1 AT 97910042 T AT97910042 T AT 97910042T AT 97910042 T AT97910042 T AT 97910042T AT E246923 T1 ATE246923 T1 AT E246923T1
Authority
AT
Austria
Prior art keywords
dfmo
breast cancer
taxol
treatment respectively
enantiomers
Prior art date
Application number
AT97910042T
Other languages
English (en)
Inventor
Alexander Weis
Richard Love
Gina Mangold
Original Assignee
Ilex Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilex Oncology Inc filed Critical Ilex Oncology Inc
Application granted granted Critical
Publication of ATE246923T1 publication Critical patent/ATE246923T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97910042T 1996-10-04 1997-10-03 Dfmo und taxol zur behandlung bzw. vorbeugung von brustkrebs ATE246923T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2783796P 1996-10-04 1996-10-04
PCT/US1997/018252 WO1998014188A1 (en) 1996-10-04 1997-10-03 Dfmo and taxol for the treatment or prevention of breast cancer

Publications (1)

Publication Number Publication Date
ATE246923T1 true ATE246923T1 (de) 2003-08-15

Family

ID=21840066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910042T ATE246923T1 (de) 1996-10-04 1997-10-03 Dfmo und taxol zur behandlung bzw. vorbeugung von brustkrebs

Country Status (6)

Country Link
EP (1) EP0871441B1 (de)
AT (1) ATE246923T1 (de)
AU (1) AU4751597A (de)
DE (1) DE69724095T2 (de)
ES (1) ES2205188T3 (de)
WO (1) WO1998014188A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462229B1 (en) * 1998-09-23 2002-10-08 Lonza Ltd. Process for the preparation of (-)-α-(difluoromethyl)ornithine-monohydrochloride monohydrate
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU3606700A (en) * 1999-02-26 2000-09-14 Napro Biotherapeutics, Inc. Treatment regimen for hormone-sensitive cancers
WO2001068076A2 (en) * 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
US6653351B2 (en) 2001-08-13 2003-11-25 Board Of Regents, The University Of Texas System Adjuvant chemotherapy for anaplastic gliomas
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
JP6508867B2 (ja) 2013-03-29 2019-05-08 キヤノン株式会社 被検体情報取得装置およびその制御方法
CN106265619A (zh) * 2016-09-29 2017-01-04 中美（河南）荷美尔肿瘤研究院 Dfmo或dfmo和姜提取物在制备食管癌和肝癌的预防及临床治疗的药物中的应用
IL314380A (en) * 2016-10-06 2024-09-01 Orbus Therapeutics Inc Preparations for administration of aflornithine
CN117701715B (zh) * 2023-12-20 2025-03-11 东莞市第八人民医院（东莞市儿童医院） Odc1及其抑制剂在乳腺癌他莫昔芬耐药诊断与治疗中的应用
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102617A (en) * 1992-07-23 1996-01-19 Technion Res & Dev Foundation Method for Assessing Clinical Sensitivity and Multidrug Resistance to Mammalian Cell Anticancer Compounds

Also Published As

Publication number Publication date
AU4751597A (en) 1998-04-24
DE69724095T2 (de) 2004-05-27
DE69724095D1 (de) 2003-09-18
EP0871441B1 (de) 2003-08-13
ES2205188T3 (es) 2004-05-01
EP0871441A1 (de) 1998-10-21
WO1998014188A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
ATE246923T1 (de) Dfmo und taxol zur behandlung bzw. vorbeugung von brustkrebs
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE215924T1 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE241378T1 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
DE69232485D1 (de) VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten.
ATE227124T1 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69715000D1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE77751T1 (de) Mittel zur behandlung von knochenkrankheiten.
DE59605959D1 (de) Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0871441

Country of ref document: EP

REN Ceased due to non-payment of the annual fee